We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Home CompaniesGrace Therapeutics, Inc.

Grace Therapeutics, Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.8481 USD -0.01 ( 0.37%)
Last update at 2026-11-12T15:15:00Z
VOLUME
3872
Market Cap
46.91M

Momentum Score

…

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.82
Low
1.85
High
52 Week Price Range
1.79
Low
5.18
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1.85
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.01
ROE
-36.19%
Net Debt
-16.98M
ROCE
-17.17%
Diluted EPS TTM
-1.14

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Income before tax -9.49M -12.77M -14.63M -51.97M -10.47M
Net income -7.79M -9.57M -12.85M -42.43M -9.82M
Selling general administrative 8.66M 7.16M 6.45M 8.08M 9.66M
Selling and marketing expenses - - 0.19M 0.14M 0.12M
Gross profit -0.01M -0.01M -0.01M -0.12M 0.00M
Reconciled depreciation 0.01M 0.01M 0.01M 0.12M 0.00M
Ebit -11.08M -16.68M -14.63M -18.25M -15.59M
Ebitda -11.07M -16.67M -14.62M -18.12M -15.34M
Depreciation and amortization 0.01M 0.01M 0.01M 0.12M -
Operating income -11.08M -16.68M -11.31M -52.16M -15.59M
Other operating expenses 11.08M 16.68M 11.31M 52.16M 15.59M
Tax provision -1.70M -3.20M -1.83M -9.54M -0.65M
Interest income 0.69M 0.71M 0.91M 0.25M 0.08M
Net interest income 0.69M 0.71M 0.91M 0.25M 0.08M
Income tax expense -1.70M -3.20M -1.78M -9.54M -0.65M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 11.08M 16.68M 11.30M 52.16M 15.59M
Cost of revenue 0.01M 0.01M 0.01M 0.12M 0.00M
Total other income expense net 1.58M 3.91M -3.32M 0.18M 5.12M
Net income from continuing ops -7.79M -9.57M -12.85M -42.43M -9.82M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total assets 66.65M 71.99M 73.30M 79.12M 128.62M
Intangible assets 41.13M 41.13M 41.13M 41.13M 69.81M
Other current assets 0.38M 0.45M 0.28M 0.60M 1.32M
Total liab 2.76M 5.38M 11.56M 11.17M 20.35M
Total stockholder equity 63.90M 66.61M 61.74M 67.95M 108.27M
Other current liab 1.44M 1.33M 0.68M 2.09M 1.37M
Common stock 0.00M 0.00M 261.04M 258.29M 257.99M
Capital stock 0.00M 0.00M 261.04M 258.29M 257.99M
Retained earnings -228.48M -220.69M -211.12M -198.27M -155.84M
Good will 8.14M 8.14M 8.14M 8.14M 12.96M
Cash 16.98M 22.13M 23.00M 27.88M 30.34M
Total current liabilities 2.15M 1.93M 1.68M 3.41M 3.26M
Net debt -16.98M -22.13M -23.00M -27.39M -30.04M
Short term debt - - - 0.07M 0.10M
Short long term debt total - - - 0.48M 0.29M
Other stockholder equity 298.41M 293.33M 17.86M 13.96M 12.15M
Total current assets 17.38M 22.71M 24.01M 29.29M 45.53M
Short term investments - - 0.00M 0.01M 13.32M
Net receivables 0.02M 0.13M 0.72M 0.80M 0.55M
Accounts payable 0.70M 0.60M 1.01M 1.24M 3.16M
Accumulated other comprehensive income -6.04M -6.04M -6.04M -6.04M -6.04M
Non currrent assets other - 0.01M - - -
Non current assets total 49.27M 49.28M 49.29M 49.83M 83.09M
Capital lease obligations - - 0.00M 0.48M 0.29M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Investments 0.00M 0.00M 0.10M 13.15M -3.52M
Total cashflows from investing activities - - 0.10M 13.15M -3.52M
Total cash from financing activities 3.71M 14.03M 7.36M 0.30M 0.00M
Net income -7.79M -9.57M -12.85M -42.43M -9.82M
Change in cash -5.16M -0.87M -4.87M -2.46M -20.60M
Begin period cash flow 22.13M 23.00M 27.88M 30.34M 50.94M
End period cash flow 16.98M 22.13M 23.00M 27.88M 30.34M
Total cash from operating activities -8.87M -14.90M -12.33M -15.91M -17.23M
Issuance of capital stock 0.00M 15.00M 7.34M 0.30M 0.00M
Depreciation 0.01M 0.01M 0.01M 0.12M 0.00M
Other cashflows from investing activities - - 0.11M - -
Change to account receivables 0.11M 0.60M 0.08M -0.30M -0.02M
Other cashflows from financing activities - -0.97M -0.14M - -
Capital expenditures 0.00M 0.00M 0.02M 0.02M 0.00M
Change in working capital 0.72M 0.34M -1.28M 0.18M -2.79M
Stock based compensation 0.80M 0.73M 0.91M 1.81M 1.34M
Other non cash items -0.90M -3.22M 2.71M 33.94M -5.32M
Free cash flow -8.87M -14.90M -12.36M -15.93M -17.23M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GRCE
Grace Therapeutics, Inc.		 -0.01
0.37%		 1.85 - 2.17 197.75 1.00 5.50 19.61
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Grace Therapeutics, Inc.

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

103 Carnegie Center, Princeton, NJ, United States, 08540

609 322 1602

https://www.gracetx.com

5

Name Title Year Born
Mr. Prashant Kohli CEO & Director 1972
Mr. Amresh Kumar Ph.D. VP of Program Management 1980
Ms. Carrie D'Andrea VP of Clinical Operations 1972
Mr. Robert J. DelAversano CPA VP of Finance and Principal Financial & Accounting Officer 1972
Dr. R. Loch MacDonald M.D., Ph.D. Member of Scientific Advisory Board & Chief Medical Officer 1962
Ms. Carrie D'Andrea Consultant 1973

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PARA
USD 0.10
+38.58%
LUNR
USD 13.91
+14.20%
MBGL
USD 22.63
+13.60%
FRMI
USD 2.04
+12.71%
FIGR
USD 26.97
+11.49%
CDNL
USD 6.09
-59.37%
ADIG
USD 11.79
-39.79%
CTVA
USD 9.21
-24.11%
BZ
USD 12.99
-22.28%
ENVX
USD 1.98
-21.70%

Equity Sectors*

  • Basic Materials

    -1.40%

  • Communication Services

    -0.45%

  • Consumer Cyclical

    -0.55%

  • Consumer Defensive

    -0.01%

  • Energy

    -0.01%

  • Financial Services

    -0.40%

  • Financials

    -0.15%

  • Healthcare

    -1.15%

  • Industrials

    -0.46%

  • Real Estate

    -0.29%

  • Technology

    -1.22%

  • Utilities

    -0.10%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…